
Description
PhaseRx is developing RNA nanomedicines for the treatment of orphan diseases. The Company’s innovative approach to drug discovery and development is based on its proprietary SMARTT Polymer Technology®, which offers effective mRNA delivery, a favorable side effect profile and robust and scalable manufacture.
Team Members
Robert Overell
President and CEO
Paul Johnson
Chief Scientific Officer
Michael Houston
VP of Therapeutics Development
Mary Prieve
Director of Biology
Sean Monahan
Director of Chemistry